Opioid Antagonist Technology for Environmental Hazard Detection and Response

Publication ID: 24-11857547_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Opioid Antagonist Technology for Environmental Hazard Detection and Response,” Published Technical Disclosure No. 24-11857547_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857547_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,547.

Summary of the Inventive Concept

The present inventive concept leverages the core technology of opioid antagonist delivery to create novel applications for detecting and responding to environmental hazards, protecting individuals in high-risk professions, and preventing opioid overdose in public spaces.

Background and Problem Solved

The original patent disclosed compositions and methods for opioid antagonist delivery, primarily focused on rescuing individuals from opioid overdose. However, the growing opioid epidemic has highlighted the need for more proactive and preventative measures. The present inventive concept addresses this limitation by applying the core technology to new use cases, providing a comprehensive solution for environmental hazard detection and response.

Detailed Description of the Inventive Concept

The new claims describe a system for detecting and responding to environmental hazards, comprising an opioid antagonist delivery module, a sensor for detecting the presence of an opioid in the environment, and a control unit for activating the delivery module upon detection of the opioid. This system can be integrated into wearable devices, public spaces, or high-risk environments to provide real-time protection against opioid exposure. The opioid antagonist delivery module utilizes the parenteral formulation disclosed in the original patent, ensuring rapid and effective response to opioid presence.

Novelty and Inventive Step

The new claims introduce a novel application of opioid antagonist technology, expanding its scope beyond individual overdose rescue to environmental hazard detection and response. The inventive step lies in the integration of sensing and control units with the opioid antagonist delivery module, enabling proactive and preventative measures against opioid exposure.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include variations in sensor technology, control unit algorithms, and opioid antagonist delivery mechanisms. For instance, the system could utilize AI-powered sensors to detect opioid presence, or incorporate additional safety features such as emergency response protocols.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in various industries, including environmental monitoring, public health, and occupational safety. Target markets include government agencies, private companies, and non-profit organizations focused on opioid epidemic mitigation and prevention.

Field of Art

Pharmaceutical formulations, medical device technology, and opioid antagonist delivery systems with expertise in pharmacokinetics, sensor technologies, and emergency medical interventions

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in pharmaceutical sciences, biomedical engineering, or related fields, possessing knowledge of drug delivery mechanisms, sensor integration, and emergency medical response technologies

Obviousness Rationale

A PHOSITA would recognize that the source patent's opioid antagonist formulation provides a foundational technology that can be readily adapted to environmental detection and response systems. The core pharmacological principles of rapid opioid antagonist delivery are directly transferable to proactive detection and intervention strategies. The technical variations in the PTD represent predictable extensions of the existing opioid antagonist delivery technology, utilizing standard engineering approaches to integrate sensing and control mechanisms.

Obvious Combinations & Variations

Source Patent Element
Parenteral formulation of nalmefene with rapid plasma concentration delivery
PTD Variation
Integration of opioid antagonist delivery module with environmental sensing system
Obviousness Reasoning
Known technique of adapting pharmaceutical formulations to new delivery contexts, with predictable results in emergency intervention technologies
Source Patent Element
Methods for pre-dosing subjects against opioid exposure
PTD Variation
Wearable device with physiological overdose detection and emergency alert system
Obviousness Reasoning
Logical progression of existing overdose prevention strategies using standard biomedical engineering design principles
Source Patent Element
Pharmaceutical compositions for opioid overdose rescue
PTD Variation
Public space opioid overdose prevention network with distributed antagonist dispensers
Obviousness Reasoning
Predictable application of existing pharmaceutical technology to broader public health intervention strategies
Source Patent Element
Nalmefene formulation for treating opioid-related medical conditions
PTD Variation
Combination therapy approach integrating opioid antagonists with complementary medical treatments
Obviousness Reasoning
Known medical technique of combining pharmaceutical agents to address complex physiological interactions
Source Patent Element
Parenteral delivery of opioid antagonist with specific adjuvant concentrations
PTD Variation
AI-powered sensor systems for detecting and responding to opioid environmental exposure
Obviousness Reasoning
Predictable technological evolution applying existing pharmaceutical knowledge to advanced sensing and intervention technologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857547, a person having ordinary skill in the art would find the technical variations disclosed in the Published Technical Disclosure to be obvious extensions of the existing opioid antagonist delivery technology. The claimed innovations represent predictable combinations of known pharmaceutical formulation principles with standard sensor and intervention technologies, thereby rendering subsequent patent claims obvious and unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,547
TitleCompositions and methods for opioid antagonist delivery
Assignee(s)Purdue Pharma L.P.